Omada Health (OMDA) Stock Price, News & Analysis

Company Overview

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management. The company integrates connected devices—such as smart scales, blood pressure monitors and activity trackers—to monitor participants’ progress and deliver real-time insights. Its multidisciplinary care teams, which include health coaches, registered dietitians and behavioral health specialists, work collaboratively to guide users toward sustainable lifestyle changes and clinical goals.

Founded in 2011 and headquartered in San Francisco, Omada Health partners with a range of stakeholders including employers, health plans and healthcare systems across the United States. Through these partnerships, the company aims to reduce the incidence and costs of chronic disease while improving long-term health outcomes. Co-founder and CEO Sean Duffy leads the organization’s strategic vision, overseeing product development and market expansion initiatives.

Key Stats

• Today's Range: $20.15 to $20.54
• 50-Day Range: $16.10 to $23.89
• 52-Week Range: $10.28 to $26.92
• Volume: 225,081 shs
• Average Volume: 1.22 million shs
• Market Capitalization: $1.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.33
• Consensus Rating: Moderate Buy

Omada Health Stock Analysis - MarketRank™

Omada Health scored higher than 64% of companies evaluated by MarketBeat, and ranked 295th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omada Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Omada Health has a consensus price target of $24.75, representing about 22.3% upside from its current price of $20.24.

Amount of Analyst Coverage

Omada Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omada Health are expected to grow in the coming year, from ($0.01) to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omada Health is -75.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omada Health is -75.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Omada Health has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.34% of the float of Omada Health has been sold short.

Short Interest Ratio / Days to Cover

Omada Health has a short interest ratio ("days to cover") of 6.87.

Change versus previous month

Short interest in Omada Health has recently increased by 2.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omada Health does not currently pay a dividend.

Dividend Growth

Omada Health does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.24

News Sentiment

Omada Health has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Omada Health this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for OMDA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Omada Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Omada Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,927,425.00 in company stock.

Percentage Held by Insiders

6.38% of the stock of Omada Health is held by insiders.

Percentage Held by Institutions

Omada Health has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/03/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/11/2026
• Investor Day 2026: 9/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:OMDA
• Previous Symbol: NASDAQ:OMDA
• CIK: 1611115
• Web: N/A
• Phone: (888) 987-8337
• Fax: N/A
• Employees: 849
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Omada Health: $24.75
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +21.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.78 million
• Net Margins: -2.22%
• Pretax Margin: -2.22%
• Return on Equity: -1.82%
• Return on Assets: -1.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.92
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $260.21 million
• Price / Sales: 4.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 5.14

Miscellaneous

• Outstanding Shares: 59,450,000
• Free Float: 55,656,000
• Market Cap: $1.21 billion
• Optionable: N/A
• Beta: 1.73